Programmed death ligand 1 (PD-L1) is a key immune checkpoint molecule that has been implicated in tumor immune escape, and the immune-modulating antibodies against PD-L1 (Atezolizumab and Durvalumab) have already been approved for the treatment of NSCLC [7,8]. Here, CD274 is linked to neoplasm.